Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 7/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 6/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | NQO1 | P15559 | 1/20 | 0.30 |
| ▸ | NQO2 | P16083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17945101 | 0.94 | ALOX5 (0.39) | ALOX5S1PR5S1PR4PTPN1CA12 | |
| SCHEMBL19082291 | 0.90 | PTPN1 (0.35) | ALOX5S1PR5S1PR4PTPN1NQO1 | |
| SCHEMBL17932226 | 0.89 | ALOX5 (0.41) | ALOX5PTPN1CA12CA1CA2 | |
| SCHEMBL17944635 | 0.88 | ALOX5 (0.38) | ALOX5PTPN1CA12CA1CA2 | |
| SCHEMBL19077445 | 0.86 | ALOX5 (0.36) | ALOX5S1PR5S1PR4CA12CA1 | |
| SCHEMBL17931902 | 0.86 | ALOX5 (0.37) | ALOX5S1PR5S1PR4CA12CA1 | |
| SCHEMBL19077444 | 0.86 | ALOX5 (0.36) | ALOX5S1PR5S1PR4PTPN1PIM1 | |
| SCHEMBL19082257 | 0.84 | ALOX5 (0.36) | ALOX5PTPN1CA12CA1CA2 | |
| SCHEMBL19077441 | 0.84 | ALOX5 (0.43) | ALOX5S1PR5S1PR4PIM1 | |
| SCHEMBL19082203 | 0.84 | PTPN1 (0.35) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10553800-B2 | Condensed cyclic compound and an organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-02-04 | — | — | US | disclosed |
| US-20170194572-A1 | CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-07-06 | — | — | US | disclosed |
| US-20170194572-A1 | CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10553800-B2 | Condensed cyclic compound and an organic light-emitting device including the same | CRY1, CRY2, CCNT1 | ALOX5 1939/4885S1PR5 4728/4885S1PR4 4594/4885 |
| US-20170194572-A1 | CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CRY2, CCNT1 | ALOX5 1939/4885S1PR5 4728/4885S1PR4 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.